Regulus Therapeutics (RGLS) News Today $1.47 +0.07 (+5.00%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have givNovember 23 at 4:51 AM | marketbeat.comRegulus Therapeutics Reports Q3 2024 Financial ResultsNovember 22 at 6:53 AM | markets.businessinsider.comReviewing Regulus Therapeutics (NASDAQ:RGLS) and CorMedix (NASDAQ:CRMD)November 17, 2024 | americanbankingnews.comFY2024 EPS Forecast for Regulus Therapeutics Cut by AnalystNovember 16, 2024 | americanbankingnews.comRA Capital Management's Strategic Reduction in Regulus Therapeutics HoldingsNovember 15, 2024 | gurufocus.comWhat is HC Wainwright's Forecast for RGLS FY2024 Earnings?Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for shares of Regulus Therapeutics in a note issued to investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the bNovember 14, 2024 | marketbeat.comRegulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy RatingNovember 12, 2024 | markets.businessinsider.comBuy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429November 12, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Regulus Therapeutics (NASDAQ:RGLS)HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday.November 11, 2024 | marketbeat.comRegulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesNovember 7, 2024 | prnewswire.comPositive Buy Rating for Regulus Therapeutics Driven by Promising Phase 1b Results and Strategic Patent AgreementNovember 1, 2024 | markets.businessinsider.comRegulus Therapeutics (NASDAQ:RGLS) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Wednesday.October 30, 2024 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on theOctober 29, 2024 | marketbeat.comBuy Rating Affirmed for Regulus Amid Promising miRNA Therapy Advances for ADPKDOctober 10, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS)HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Tuesday.October 8, 2024 | marketbeat.comRegulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 8, 2024 | prnewswire.comCVI Holdings LLC Cuts Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)CVI Holdings LLC decreased its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 71.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 401,012 shares of the biopharmaceutical company's stock after selling 1,005,2September 28, 2024 | marketbeat.comStockNews.com Upgrades Regulus Therapeutics (NASDAQ:RGLS) to "Sell"StockNews.com raised shares of Regulus Therapeutics to a "sell" rating in a research note on Tuesday.September 17, 2024 | marketbeat.comRegulus Therapeutics Inc (7RG0.SG)September 16, 2024 | uk.finance.yahoo.comRegulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesAugust 28, 2024 | prnewswire.comVanguard Group Inc. Boosts Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)Vanguard Group Inc. boosted its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 158.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 740,215 shares of the biopharmaceutical company's stock aftAugust 20, 2024 | marketbeat.comCompanies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In GrowthAugust 14, 2024 | finance.yahoo.comRegulus Therapeutics (NASDAQ:RGLS) Stock Rating Reaffirmed by OppenheimerOppenheimer reiterated an "outperform" rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday.August 14, 2024 | marketbeat.comRegulus Therapeutics Inc. Forecasted to Earn Q2 2025 Earnings of ($0.20) Per Share (NASDAQ:RGLS)Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Regulus Therapeutics in a note issued to investors on Thursday, August 8th. Leerink Partnrs analyst J. Schwartz expects that the biopharmaceutical comAugust 12, 2024 | marketbeat.comBuy Rating Reaffirmed for Regulus Therapeutics Amidst Promising Clinical Data and Progress Towards Pivotal TrialAugust 10, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS)HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research note on Friday.August 9, 2024 | marketbeat.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024August 9, 2024 | investorplace.comRegulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesAugust 8, 2024 | prnewswire.comRegulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceAugust 6, 2024 | prnewswire.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at OppenheimerOppenheimer initiated coverage on shares of Regulus Therapeutics in a research note on Friday. They issued an "outperform" rating and a $7.00 target price for the company.August 2, 2024 | marketbeat.comBuy Rating Affirmed for Regulus Therapeutics on RGLS8429’s Potential in ADPKD MarketAugust 1, 2024 | markets.businessinsider.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest UpdateRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the target of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 4,340,000 shares, a decline of 18.1% from the June 30th total of 5,300,000 shares. Approximately 8.2% of the company's shares are short sold. Based on an average daily volume of 817,600 shares, the days-to-cover ratio is presently 5.3 days.July 28, 2024 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rJuly 21, 2024 | marketbeat.comCVI Holdings LLC Makes New $4.05 Million Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)CVI Holdings LLC bought a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,406,250 shares of the biopharmaceutical company's stock, valued at apJuly 14, 2024 | marketbeat.comShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Grows By 48.0%Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 5,300,000 shares, an increase of 48.0% from the June 15th total of 3,580,000 shares. Based on an average trading volume of 798,700 shares, the days-to-cover ratio is presently 6.6 days. Approximately 10.0% of the shares of the company are short sold.July 12, 2024 | marketbeat.comRegulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesJuly 9, 2024 | prnewswire.comRegulus Therapeutics Inc. to Post Q1 2025 Earnings of ($0.20) Per Share, HC Wainwright Forecasts (NASDAQ:RGLS)Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Regulus Therapeutics in a research note issued on Tuesday, June 25th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will posJune 26, 2024 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have givJune 26, 2024 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) PT Raised to $28.00Canaccord Genuity Group boosted their price target on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a "buy" rating in a research report on Tuesday.June 25, 2024 | marketbeat.comRegulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 24, 2024 | prnewswire.comRegulus Therapeutics (NASDAQ:RGLS) Stock Crosses Above Two Hundred Day Moving Average of $1.87Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200-Day Moving Average of $1.87June 19, 2024 | marketbeat.comRegulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesJune 4, 2024 | prnewswire.comRegulus Therapeutics Inc.: Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerMay 16, 2024 | finanznachrichten.deRegulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerMay 16, 2024 | prnewswire.comStarwatch: the moon celebrates with a cruise past RegulusMay 13, 2024 | theguardian.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Down 32.9% in AprilRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 4,210,000 shares, a decline of 32.9% from the April 15th total of 6,270,000 shares. Based on an average daily volume of 3,040,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 7.3% of the shares of the company are short sold.May 12, 2024 | marketbeat.comBuy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429May 10, 2024 | markets.businessinsider.comRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 10, 2024 | finanznachrichten.deRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024May 9, 2024 | msn.comRegulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 9, 2024 | prnewswire.com Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. RGLS Media Mentions By Week RGLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGLS News Sentiment▼-0.060.50▲Average Medical News Sentiment RGLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGLS Articles This Week▼31▲RGLS Articles Average Week Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alimera Sciences News XOMA News Codexis News Vanda Pharmaceuticals News Lexicon Pharmaceuticals News Verastem News Achieve Life Sciences News Agenus News Fortress Biotech News SAB Biotherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGLS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGLS Stock Alerts